# Development of a Therapeutic to Treat Anthrax in Humans

> **NIH NIH N01** · HAWAII BIOTECH, INC. · 2021 · $69,252

## Abstract

To support the advanced development of a promising small molecule antitoxin against Anthrax.  The research and development activities to be supported will allow this candidate therapeutic product to progress through the product development pathway, and include preclinical and non-clinical activities, IND regulatory development activities, and Phase I clinical safety assessment.

## Key facts

- **NIH application ID:** 10480716
- **Project number:** 272201800023C-P00010-9999-1
- **Recipient organization:** HAWAII BIOTECH, INC.
- **Principal Investigator:** ALAN JOHNSON
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $69,252
- **Award type:** —
- **Project period:** 2018-09-21 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10480716

## Citation

> US National Institutes of Health, RePORTER application 10480716, Development of a Therapeutic to Treat Anthrax in Humans (272201800023C-P00010-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10480716. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*